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Abstract  
Connective tissue growth factor (CTGF) has been reported in gastric adenocarcinoma and in 
carcinoid tumors. The aim of this study was to explore a possible link between CTGF and gastrin 
in gastric epithelial cells and to study the role of CTGF in gastrin induced migration and invasion 
of AGS-GR cells. The effects of gastrin were studied using RT-qPCR, Western blot and assays 
for migration and invasion. We report an association between serum gastrin concentrations and 
CTGF abundancy in the gastric corpus mucosa of hypergastrinemic subjects and mice. We found 
a higher expression of CTGF in gastric mucosa tissue adjacent to tumor compared to normal 
control tissue. We showed that gastrin induces expression of CTGF in gastric epithelial AGS-GR 
cells via MEK, PKC and PKB/AKT pathways. CTGF inhibited gastrin induced migration and 
invasion of AGS-GR cells. We conclude that CTGF expression is stimulated by gastrin and 
involved in remodeling of the gastric epithelium. 
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Highlights: 
 CTGF is overexpressed in gastric cancer and adjacent tissue compared to normal gastric 
tissue. 
 Gastrin induces expression of CTGF in gastric epithelial cells. 
 CTGF inhibits gastrin induced migration and invasion of AGS-GR cells. 
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Introduction 
 
The CCN proteins are a family of matricellular proteins involved in many physiological and 
pathological processes, including carcinogenesis. The connective tissue growth factor (CTGF), 
also known as CCN2, is believed to interact with a wide range of molecules by virtue of its multi-
domain structure. Such interactions enable CTGF to modulate and integrate different biological 
cues into a cognate biological response. CTGF is a prominent mediator of transforming growth 
factor β (TGFβ) signalling [1]. It interacts with components of extracellular matrix (ECM) and 
various cell surface receptors regulating cell and cell-matrix signalling [1]. CTGF is involved in 
tuning of cell adhesion, migration, extracellular matrix production, survival and tumorigenesis 
[2]. Furthermore, CTGF promotes migration of many mesenchymal cell types and has been 
identified in a variety of tumors, including gastric cancer [2-4].  
 
The gastric hormone gastrin is well known for its role in stimulating gastric acid secretion and 
organization of the gastric mucosa by promoting epithelial cell proliferation, migration and 
invasion [5]. Gastrin is identified to regulate expression of molecules that exert important effects 
on extracellular matrix remodelling, including plasminogen activator inhibitors (PAIs) [6] and 
matrix metalloproteinases (MMPs) [7]. 
 
CTGF has been suggested to be involved in the neoplastic transformation of gastrointestinal 
neuroendocrine cells and has been reported in carcinoids [8, 9]. Here we have assessed the 
hypothesis that gastrin regulates gastric CTGF expression and explored a potential role of CTGF 
in gastrin induced migration and invasion of gastric epithelial cells.  
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Materials and methods 
 
Cells, plasmids and reagents. AGS-GR cells were maintained as previously described [10]. CTGF 
expression vector was obtained from Open Biosystems (Thermo Scientific, Rockford, IL, USA) 
and empty pCMV vector from Addgene (Cambridge, UK). siRNA for CTGF,  STAT3 and 
control siRNA were respectively obtained from Invitrogen (Carlsbad, CA, USA), Qiagen 
(Germantown, MD, USA) and Ambion (Austin, TX, USA). Human recombinant CTGF was 
obtained from Peprotech (London, UK). Gastrin (G-17) was purchased from Sigma-Aldrich (St. 
Louis, MO, USA). The inhibitors Ro 31-8220 (3-[1-[3-(Amidinothio) propyl]-1H-indol-3-yl] -3-
(1-methyl-1H-indol-3-yl) maleimide, Bisindolylmaleimide IX, Methanesulfonate) and AKT 
inhibitor XVIII, SC 66 ((2E, 6E)-2, 6-bis (4-Pyridylmethylene) cyclohexanone) were obtained 
from Millipore (Merck KGaA, Darmstadt, Germany). BIRB 796 (Doramapimod), PD184352 
(C17H14ClF2IN2O2) and SB203580 (C21H16FN3OS) were obtained from Axon Medchem 
(Groningen, NL).  
 
Patients and mice. Four subjects with normal (24.3 ± 2.2 pM) and four patients with high (67 ± 
12.7 pM) plasma gastrin concentrations were selected from a cohort, aged 18 and over, who had 
clinical indications for undergoing upper gastrointestinal endoscopy. The study was approved by 
the Liverpool Local Research Ethics Committee and by the Royal Liverpool and Broadgreen 
University Hospitals NHS Trust and all patients gave written, informed consent. Corpus biopsies 
were collected in RIPA buffer and extracts were prepared as previously described [11]. In 
addition, four INS-Gas mice with elevated plasma gastrin (348.8 ± 184.1pM) and FYB/N wild 
type controls with normal plasma gastrin (73.5 ± 12.8pM) concentrations were maintained in an 
appropriately controlled environment with a 12-12 h light/dark cycle and were fed a commercial 
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pellet diet with water ad libitum as previously described [7] [12]. Animals were killed by 
increasing CO2 concentration. Gastric corpus extracts were prepared from unfasted animals in 
RIPA buffer as previously described [11]. All animal experiments were approved by the 
University of Liverpool Animal Welfare Committee, and were conducted in compliance with 
Home Office requirements and the UK Animals (Scientific Procedures) Act 1986.  
 
The human materials used for microarray gene expression analysis were biopsies from gastric 
adenocarcinoma (n=61) and adjacent (non-tumor) mucosa (n=21) from patients, and age-sex 
matched normal mucosa form healthy individuals (n=16), collected at St.Olavs Hospital, 
Trondheim, Norway. The patients gave written informed consent and the study was approved by 
the Regional Medical Research Ethics Committee of Central Norway (Approval No. 018-02). 
Samples were kept frozen at -80°C until further processing. 
 
Gastrin radioimmunoassay. Mouse plasma and human serum samples were assayed for total 
amidated gastrin concentrations by radioimmunoassay using antibody L2 (which reacts with G-
17 and G-34 but not progastrin or Gly-gastrins) and 125I-G-17 as previously described [13].  
 
Immunohistochemistry. Tissue sections were deparaffinised, rehydrated, quenched for 
endogenous peroxidase before antigen retrieval in boiling citrate buffer. The sections were 
incubated with mouse anti-CgA (M0869, Dako, Glostrup, Denmark) (1:1500) or goat anti-CTGF 
(sc-14939, Santa Cruz Biotechnology, Dallas, TX, USA) (1:200) overnight at 4˚C. Reactions 
were visualized using room temperature incubation with the rabbit/mouse EnVision-
HRP/DAB+kit (K5007, Dako), or biotinylated anti-goat (BA-5000, Vector Laboratories, 
Birlingame, CA, USA) (1:150) for 1h, ABC reagent (PK-6100, Vectastain Elite ABC Kit 
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(Standard), Vector Laboratories) for 30 min, and DAB chromogen (K5007, Dako). Hematoxylin 
was used as counterstain. Serial staining was done on the shared surface of neighbouring 
sections.  
 
RNA extraction. AGS-GR cells (2x10
5) were plated in 6-well plates in complete medium. After 
48h, cells were treated with G-17 (5nM, 1h) in serumfree medium.  In the experiments with 
kinase inhibitors, cells were pretreated with inhibitors for 1h prior to G-17 treatment. RNeasy 
Mini kit (Qiagen, Germantown, MD, USA) was used for total RNA extraction, following 
instructions provided by the manufacturer. Assessment of RNA integrity, quality and quantity 
were performed with a Nanodrop spectrophotometer (Nanodrop Technologies, Rockland, DE, 
USA).  
Total RNA from the frozen stomach samples was isolated and purified using an Ultra-Turrax 
rotating-knife homogenizer and the mirVana miRNA Isolation Kit (Ambion, Thermo Fisher 
Scientific Inc., DE, USA) according to the manufacturer’s instructions. 
 
cDNA synthesis and quantitative real-time PCR (RT-qPCR). Aliquots of 1μg of total RNA were 
reverse transcribed using Transcriptor First strand cDNA synthesis Kit (Roche Applied Science, 
Mannheim, Germany). cDNAs were amplified with the FastStart Universal SYBR Green Master 
(Rox) (Roche). The thermal cycling program used was: 5min at 95°C, then 40 cycles of 30s at 
95°C, 30s at 60°C and 30s at 72°C followed by melting curve analysis. Relative CTGF mRNA 
abundance was calculated by 2-ΔΔCT method [14]. All PCR reactions were performed in triplicates 
on StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and 
normalized by comparison to β-actin.  Primer and probe sequences are shown in Suppl. Table 1. 
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Microarray gene expression analysis. cRNA was prepared with Ambion's Illumina® 
TotalPrep™-96 RNA Amplification Kit, using 300 ng total as input material. For each sample, 
the biotin-labelled cRNA concentrations were checked (NanoDrop, Thermo Fisher Scientific) 
and 750 ng hybridized to HumanHT-12 Expression BeadChips (Illumina, CA, USA). Only 
probes abiding to the Illumina detection p value of 0.01 in at least one sample were included in 
further analyses, using the limma (v. 3.12.1) Bioconductor package [15] for paired t-tests. A false 
discovery rate adjusted P value <0.05 was taken as significant. The microarray data are available 
from ArrayExpress (accession no. E-MTAB-1338). 
 
Western blot. For the patient samples, western blot analysis was performed as described in [7] 
using antibodies to CTGF (Santa Cruz Biotechnology). AGS-GR cells (2x10
5 or 3x105 /well) were 
plated in 6-well plates and grown for 48h. After G-17 (5nM, 1h) stimulation, the cells were 
harvested in 200 µl RIPA (Pierce, Thermo Scientific). Proteins were resolved using NuPAGE 
Novex 10% Bis-Tris Gels (Invitrogen), transferred to polyvinylidene difluride (PVDF) membrane 
(Millipore, Merck KGaA, Darmstadt, Germany) and probed with anti-CTGF (1:400) (Santa Cruz 
Biotechnology) followed by HRP-conjugated secondary antibody, detected by SuperSignal® 
West Femto Maximum Sensitivity Substrate (Pierce, Thermo Scientific) and visualized with 
Odyssey FC Dual Mode imaging system (LI-COR, Lincoln, NE, USA). The blots were quantified 
with Image studio version 3.1 (LI-COR, Lincoln). Blots were reprobed for β-actin to normalise 
for protein loading. 
 
Transient transfection. AGS-GR cells (3.5x10
5/well) were plated in 6-well plates and transfected 
after 24h with 2.5µg of plasmid (pCMV-CTGF or control pCMV) or siRNA  and 12.5µl 
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Metafectene PRO transfection reagent (Biontex Laboratories GmbH, Martinsried, Germany) per 
well.  
 
Migration and invasion assays. Biocoat Cell Culture Inserts (migration assays) or Matrigel-
coated inserts (invasion assays) (BD Biosciences, Bedford, MA, USA) were performed according 
to the manufacurer’s instructions and as described in [6].  
 
Statistical analysis. Results are presented as means ± SEM. Comparisons between data were 
made using paired Students t-test and were considered significant at P<0.05.   
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Results 
 
Gastric CTGF is increased in hypergastrinemia and in gastric adenocarcinomas. 
To investigate if gastric mucosal CTGF is associated with elevated plasma gastrin, gastric corpus 
biopsies selected from individuals with either low or high gastrin were processed for detection of 
CTGF by Western blot. In both cases, there was a major band with size 50 kDa (Fig. 1A). In 
subjects with high plasma gastrin, the abundance of detected protein was significantly increased 
compared to subjects with normal plasma gastrin (P<0.05) (Fig. 1A and B). We then examined 
CTGF by Western blot of gastric corpus extracts from an animal model of hypergastrinemia, the 
INS-Gas mouse [16]. Again, there was a major band of 50 kDa and a significant increase of this 
protein in hypergastrinemic mice compared to normal wild type mice (P<0.05) (Fig. 1C and D). 
 
The expression pattern of CTGF in human gastric mucosa (n=10) was also observed by 
immunohistochemistry, showing expression mostly in epithelial cells. Some scattered, single 
cells strongly expressed CTGF (Fig. 1F), and these were also positive for the neuroendocrine 
marker CgA in serial sections (Suppl. Fig. 1). To analyse the expression of CTGF in human 
gastric adenocarcinoma tissues, microarray gene expression analysis was performed. 
Comparisons of gene expression patterns between tumor, adjacent mucosa and normal mucosa 
showed upregulated expression of CTGF in adjacent mucosa (log2 fold change 2.8, P<0.001) and 
in tumor (log2 fold change 3.1, P<0.001) compared to normal controls. No significant regulation 
was detected between tumor vs adjacent mucosa. CTGF overexpression was verified using RT-
qPCR (CTGF in adjacent mucosa (log2 fold change 3.9, P<0.001) and in tumor (log2 fold change 
3.1, P<0.001) compared to normal controls) and also confirmed at protein level using 
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immunohistochemistry. Both tumors (n=17) and adjacent mucosa (n=5) showed increased 
expression of CTGF compared to normal control mucosa (Fig. 1F). 
 
Gastrin induces expression of CTGF transcripts via MEK, PKC and PKB/AKT.  
To study the molecular mechanisms by which gastrin induces CTGF, RT-qPCR and Western blot 
experiments were performed. Gastrin induced a concentration dependent increase in CTGF 
expression that was maximal 1h and 6h after stimulation, respectively, for CTGF mRNA and 
protein (Fig. 2). The MEK inhibitor PD 184352 repressed the gastrin induced expression of 
CTGF in a dose dependent manner (Fig. 3A). The response was also inhibited by Ro-31-8220 
(Fig. 3B), which is an inhibitor to PKC, and by the specific AKT Inhibitor XVIII, SC66 (Fig. 
3C), indicating activation of MEK 1/2, PKC and AKT by gastrin  and its involvement in 
transducing signals required for expression of CTGF. The p38MAPK inhibitors SB203580 and 
BIRB 796 had no effect on CTGF expression (Suppl. Fig. 2). 
A previous study has recognized STAT-3 as an important regulator of TGF-β induced CTGF 
expression [17]. However, gastrin stimulated CTGF was not influenced by knocking down 
STAT-3 in AGS-GR cells (Suppl. Fig. 3).  
 
CTGF suppresses gastrin induced migration and invasion. 
Since CTGF is implicated in control of cell migration and invasion we examined the role of 
CTGF on gastrin stimulated migration and invasion of AGS-GR cells in Boyden chambers. 
Addition of exogenous recombinant CTGF significantly inhibited the gastrin induced migration 
and invasion (Fig. 4A and B). Knockdown of CTGF resulted in a significant increase of 
migration and invasion and gastrin treatment further enhanced this effect (Fig. 4C and D). 
Ectopic expression of CTGF dramatically reduced the number of migrating and invading cells as 
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a consequence of gastrin treatment (Fig. 4E and F). Collectively, these results suggest that CTGF 
inhibits the migratory and invading potential of AGS-GR cells. Downregulation and 
overexpression of CTGF mRNA and protein was verified by qPCR and Western blotting (Suppl. 
Fig. 4). 
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Discussion 
 
A high expression of CTGF has been reported in gastric cancer [3, 4, 18] and this is confirmed in 
the present study. In addition, our results (microarray and IHC) show that CTGF is upregulated in 
adjacent (non-tumor) mucosa from patients with gastric adenocarcinoma compared to normal 
tissue, but not in tumor compared to adjacent tissue, implicating a likely role of CTGF in early 
gastric cancer development. This observation supports previous suggestion that CCN family 
proteins play a role in the initiation stage of gastric cancer development [19].  
A 50 kDa major band was observed when analyzing hypergastrinemic patients and mice tissue by 
Western blot using a CTGF antibody. The 50 kDa band of CTGF, corresponding to the band 
observed in the current study, has previously been described [20]. It is likely that the 50 kDa band 
is a stable aggregate of CTGF fragments, or CTGF fragments tightly associated to other growth 
factors. The CTGF belongs to a big family of CCN proteins, consisting of a large number of 
processing products. Further studies are needed to identify the CTGF fragments observed. 
In the present study, we found that gastrin induces expression of CTGF. AGS-GR cells treated 
with gastrin were shown to express CTGF in a time and dose dependent manner, both at mRNA 
and protein level. The results suggest involvement of PKC, PKB/AKT and MEK/ERK pathways 
in transducing the gastrin signal to induce CTGF gene expression. These pathways are known to 
be activated by gastrin [21]. However, the pathways have not previously been shown to be 
involved in gastrin induced expression of CTGF. Furthermore, observations form this study show 
that CTGF attenuates gastrin induced migration and invasion of AGS-GR cells. 
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It is clear that gastrin stimulates expression of a number of genes involved in mucosal 
organization and protection [5]. The fact that gastrin may upregulate expression of molecules 
with apparently opposite effects on matrix modelling such as PAIs and MMPs indicate that the 
mechanisms involved are likely to be complex. CTGF probably influence the balance of opposite 
effects. CTGF mRNA has been shown to correlate with both PAI-1 and tissue inhibitors of 
MMPs (TIMPs), both markers of tissue turnover [22]. Previous studies document a complex 
network of both similar and unique signalling cascades leading to induction of PAI-1 and CTGF 
in response to modifications in cytoskeletal structure [23]. 
Previous studies have reported that CTGF may be positively involved in gastric cancer 
progression. High CTGF expression has been shown to correlate with more lymph node 
metastasis, more peritoneal dissemination, and a shorter survival of gastric cancer patients [3, 4, 
24]. Downregulation of CTGF in gastric cancer cells has been shown to reduce peritoneal 
dissemination in a nude mouse model [24]. Previous studies in vitro have demonstrated that 
knockdown of CTGF decreases proliferation and colony formation of gastric cancer cells. After 
CTGF knockdown, gastric cancer cells also show less migration/invasion abilities with decreased 
protein expression and proteolytic activity of both MMP-1 and MMP-9 [24]. Moreover, CTGF 
has been shown to promote gastric cancer cell adhesion to peritoneum [25]. However, in our 
model system using AGS-GR cells, CTGF was demonstrated to inhibit gastrin induced migration 
and invasion. Our results are compatible with previous results showing that CTGF inhibits gastric 
cancer peritoneal metastasis by blocking integrin-dependent adhesion [26]. Differences in in vitro 
migration/invasion results may be due to variable use of serum in the experimental setups [18].   
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Taken together, these results indicate that CTGF may play different roles in different cancers and 
different settings/model systems. CTGF may play a role both in the initial stage of GC 
carcinogenesis and in later stages (invasion and metastasis) [19]. 
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Figure legends 
 
Fig. 1. Increased CTGF in corpus biopsies from hypergastrinemic humans and mice, in human 
gastric adenocarcinomas and adjacent tissue compared to normal controls. 
(A) Western blot showing the major CTGF band in gastric corpus biopsies from four subjects 
with serum gastrin <30 pm (Hi-gas, -) and four subjects with hypergastrinemia (Hi-gas, +). (B) 
Abundance of the CTGF band estimated by densitometry of Western blots by the data shown in 
A. Means ± SEM. (C) Western blot showing the major CTGF band (50 kDa) in gastric corpus 
biopsies from four wild-type mice and four INS-Gas hypergastrinemic mice. (D) Abundance of 
the major CTGF band estimated by densitometry of the Western blot of data shown in C. Means 
± SEM. (E) Gene expression analysis of CTGF (ILMN_2115125, Illumina Human HT-12), 
showing increased CTGF levels in human gastric adenocarcinoma and adjacent non-tumor) tissue 
compared to age-sex matched normal control gastric tissue. The symbols represent individual 
mRNA expression levels (log2 intensities) in the designated groups, with the line indicating 
median. (F) Immunohistochemical staining showing expression of CTGF (brown) in mucosa 
from normal control and adjacent non-tumor gastric tissue. The strongest expressing cells 
probably represent neuroendocrine cells (Suppl. Fig. 1). Scale bars 50 µm. 
 
Fig. 2. Time and dose dependent induction of CTGF by gastrin in AGS-GR cells. 
(A) Expression of CTGF mRNA in response to G-17 (5 nM) was maximal after 1h. Mean ± SEM 
of three independent experiments. * P<0.05. All measurements were performed in triplicates. 
 (B) G-17 (5 nM) enhances CTGF protein abundance relative to β-actin in AGS-GR cells. Data 
represent one of three biological replicas.  
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(C) Progressive increase in expression of CTGF with concentrations of G-17 (1h) from 0.5 to 10 
nM. Mean ± SEM of three independent experiments. * P<0.05. All measurements were 
performed in triplicates. 
 (D) Dose dependent effects of G-17 (treated for 4h) on CTGF protein abundance relative to β-
actin. Data represent one of three biological replicas. 
 
Fig. 3. Inhibition of G-17 stimulation of CTGF by the inhibitors PD 184352, Ro 31-8220 and 
XVIII, SC66. 
 (A) Suppression of G-17 (5 nM, 1h) induced CTGF transcript in response to various 
concentrations of PD 184352. (B) Ro 31-8220 inhibits G-17 (5 nM, 1h) induced expression of 
CTGF in a dose dependent fashion.  
(C). The AKT Inhibitor XVIII, SC66 inhibits G-17 (5 nM, 1h) induced expression of CTGF.  
Means ± SEM of three independent experiments. * P<0.05. All measurements were performed in 
triplicates. 
 
Fig. 4. CTGF inhibits gastrin induced migration and invasion of AGS-GR. cells. 
(A) Exogenously added CTGF attenuates both basal and G-17 (0.3 nM, 18h) induced migration 
of AGS-GR cells. Means ± SEM of three independent experiments. * P<0.05. All measurements 
were performed in triplicates. 
(B) Addition of recombinant CTGF cells attenuates G-17 (0.3 nM, 24h) induced invasion of 
AGS-GR cells. Means ± SEM of two independent experiments. * P<0.05. All measurements were 
performed in triplicates. 
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(C) Migration of unstimulated AGS-GR cells is stimulated by G-17 (0.3 nM, 18h), and the 
response is increased in CTGF siRNA treated cells. Means ± SEM of three independent 
experiments. * P<0.05. All measurements were done in triplicates.  
(D) siRNA knockdown of CTGF enhances gastrin induced invasion of AGS-GR cells. Means ± 
SEM of three independent experiments. All measurements were done in triplicates.  
(E) Ectopic expression of CTGF inhibits G-17 (0.3 nM, 18h) induced migration of AGS-GR cells. 
Means ± SEM of eight independent experiments. * P<0.05. All measurements were done in 
triplicates. (F) Ectopic expression of CTGF inhibits G-17 (0.3 nM, 24h) induced invasion. Means 
± SEM of five independent experiments. * P<0.05. All measurements were done in triplicates. 
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Suppl. Table 1 
The table shows primers and TaqMan probe sequences used for CTGF and β-actin gene. 
 
Gene  
CTGF S-5’-TGC AGG CTA GAG AAG CAG AG-3’ 
 AS-5’-GCC CTT CTT AAT GTT CTC TTC C-3’ 
 P-5’-TTC GCA AGG CCT GAC CAT GC-3’ 
β-actin S-5’- TGA GCG CGG CTA CAG CTT-3’ 
AS-5’- CC TTA ATG TCA CGC ACG ATT T-3’ 
P-5’-ACC ACC ACG GCC CAG CGG-3’  
S= sense, AS= antisense,  P=TaqMan probe 
  
26 
 
Supplementary figures  
 
 
 
 
 
Suppl. Fig. 1. Colocalization of CTGF and CgA in gastric epithelial cells.   
Immunohistochemical staining showing strong CTGF expression in cells that also express the 
neuroendocrine marker CgA (arrows) in stained serial sections from normal control gastric 
mucosa. * = identical positions. Scale bars 50 µm.   
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Suppl. Fig. 2. p38MAPK inhibitors SB203580 and BIRB 796 had no effect on CTGF expression. 
(A) SB 203580 treatment of AGS-GR cells showed poor inhibition of G-17 (5 nM, 1h) induced 
CTGF. (B) Blockage of p38 MAPK using BIRB 796 had no negative effect on G-17 (5 nM, 1h)   
induced level of CTGF. At higher micromolar concentration of BIRB 796, unspecific side effects 
are seen.  
The bars show the mean ± SEM of the three technical replicates. Similar results were obtained 
from three independent experiments. One representative experiment is shown. 
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Suppl. Fig. 3. STAT-3 is not essential for G-17 mediated expression of CTGF. 
(A) Decreased abundance of STAT-3 after knockdown of STAT-3 by siRNA treatment compared 
with control siRNA. Cells treated with siRNA against STAT-3 revealed 76% knockdown in G-17 
(5 nM, 1h) treated sample and 50% in untreated sample. (B) No significant change in expression 
of CTGF in STAT-3 siRNA knockdown cells compared with siRNA control treated AGS-GR 
cells.  
The results shown are one representative of two independent experiments. The bars above 
represent the relative abundance of STAT3/CTGF protein compared to β-actin. 
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Suppl. Fig. 4. Verification of knockdown and overexpression of CTGF mRNA and protein. 
(A-B) Decreased abundance of CTGF mRNA (A) and protein (B) after knockdown of CTGF 
using siRNA compared with control siRNA. (C-D) Overexpression of CTGF mRNA (C) and 
protein (D) in AGS-GR transfected with pCMV-CTGF compared to pCMV empty vector and 
untransfected control cells. Cells were stimulated with G-17 (5 nM, 1h). One representative of 
two independent experiments is shown. The bars in (C) indicate mean ± SEM of the three 
technical replicates representing relative CTGF mRNA abundancy normalized to β-actin. 
